|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q80423963
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010855.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q80423963
|
|
024
|
|
|
‡a
0000-0001-8765-3044
‡2
orcid
|
|
035
|
|
|
‡a
(OCoLC)Q80423963
|
|
100
|
0 |
|
‡a
Gilberto de Castro
‡c
researcher
‡9
en
|
|
400
|
0 |
|
‡a
Gilberto de Castro
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition
|
|
670
|
|
|
‡a
Author's Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
|
|
670
|
|
|
‡a
Author's An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.
|
|
670
|
|
|
‡a
Author's ATAC trial update
|
|
670
|
|
|
‡a
Author's BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
|
|
670
|
|
|
‡a
Author's Building research capacity and clinical trials in developing countries.
|
|
670
|
|
|
‡a
Author's Cost-effectiveness analysis of cisplatin-based chemoradiation to treat patients with unresectable, nonmetastatic head and neck cancer in Brazil
|
|
670
|
|
|
‡a
Author's Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: Consensus opinion from a panel of experts
|
|
670
|
|
|
‡a
Author's Economic analyses in squamous cell carcinoma of the head and neck: a review of the literature from a clinical perspective
|
|
670
|
|
|
‡a
Author's ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation
|
|
670
|
|
|
‡a
Author's Exercise prescription for symptoms and quality of life improvements in lung cancer patients: a systematic review
|
|
670
|
|
|
‡a
Author's First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
|
|
670
|
|
|
‡a
Author's Head and neck cancer emerging strategies: advances and new challenges
|
|
670
|
|
|
‡a
Author's Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis.
|
|
670
|
|
|
‡a
Author's Influence of time between surgery and postoperative radiation therapy and total treatment time in locoregional control of patients with head and neck cancer: a single center experience
|
|
670
|
|
|
‡a
Author's Keynote comment: reimbursement for molecularly targeted anticancer agents
|
|
670
|
|
|
‡a
Author's Lung Cancer and the COVID-19 pandemic: Recommendations from the Brazilian Thoracic Oncology Group
|
|
670
|
|
|
‡a
Author's Lung cancer in Brazil
|
|
670
|
|
|
‡a
Author's Management of advanced head and neck squamous cell carcinoma in elderly patients
|
|
670
|
|
|
‡a
Author's Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
|
|
670
|
|
|
‡a
Author's Next-generation sequencing of circulating tumor DNA for metastatic non-small cell lung cancer: a discussion on its implementation in the Brazilian clinical practice
|
|
670
|
|
|
‡a
Author's Oral Mucositis Prevention By Low-Level Laser Therapy in Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy: A Phase III Randomized Study
|
|
670
|
|
|
‡a
Author's Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy
|
|
670
|
|
|
‡a
Author's Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC
|
|
670
|
|
|
‡a
Author's Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
|
|
670
|
|
|
‡a
Author's Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations
|
|
670
|
|
|
‡a
Author's Review: side effects of approved molecular targeted therapies in solid cancers.
|
|
670
|
|
|
‡a
Author's Second primary cancers in head and neck cancer patients: a challenging entity
|
|
670
|
|
|
‡a
Author's Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
|
|
670
|
|
|
‡a
Author's Targeting the immune system in head and neck cancer
|
|
670
|
|
|
‡a
Author's The importance of molecular characterization in lung cancer
|
|
670
|
|
|
‡a
Author's Tongue cancer in the young
|
|
909
|
|
|
‡a
(orcid) 0000000187653044
‡9
1
|
|
919
|
|
|
‡a
afatinibversusmethotrexateinolderpatientswith2linerecurrentandormetastaticheadandnecksquamouscellcarcinomasubgroupanalysisoftheluxheadandneck1trial
‡A
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial
‡9
1
|
|
919
|
|
|
‡a
openlabelmulticenterrandomizedphase2studyofcisplatinandpemetrexedwithorwithoutcixutumumabimca12asa1linetherapyinpatientswithadvancednonsquamousnonsmallcelllungcancer
‡A
An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer.
‡9
1
|
|
919
|
|
|
‡a
atactrialupdate
‡A
ATAC trial update
‡9
1
|
|
919
|
|
|
‡a
brafmutationsinnonsmallcelllungcancerhasfinallyjanusopenedthedoor
‡A
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
‡9
1
|
|
919
|
|
|
‡a
buildingresearchcapacityandclinicaltrialsindevelopingcountries
‡A
Building research capacity and clinical trials in developing countries.
‡9
1
|
|
919
|
|
|
‡a
costeffectivenessanalysisofcisplatinbasedchemoradiationtotreatpatientswithunresectablenonmetastaticheadandneckcancerinbrazil
‡A
Cost-effectiveness analysis of cisplatin-based chemoradiation to treat patients with unresectable, nonmetastatic head and neck cancer in Brazil
‡9
1
|
|
919
|
|
|
‡a
criteriaforeligibilitytocisplatininthecurativetreatmentofheadandneckcancerconsensusopinionfromapanelofexperts
‡A
Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: Consensus opinion from a panel of experts
‡9
1
|
|
919
|
|
|
‡a
economicanalysesinsquamouscellcarcinomaoftheheadandneckareviewoftheliteraturefromaclinicalperspective
‡A
Economic analyses in squamous cell carcinoma of the head and neck: a review of the literature from a clinical perspective
‡9
1
|
|
919
|
|
|
‡a
ercc1proteinmrnaexpressionandt19007cpolymorphismasprognosticmarkersinheadandnecksquamouscellcarcinomapatientstreatedwithsurgeryandadjuvantcisplatinbasedchemoradiation
‡A
ERCC1 protein, mRNA expression and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma patients treated with surgery and adjuvant cisplatin-based chemoradiation
‡9
1
|
|
919
|
|
|
‡a
exerciseprescriptionforsymptomsandqualityoflifeimprovementsinlungcancerpatientsasystematicreview
‡A
Exercise prescription for symptoms and quality of life improvements in lung cancer patients: a systematic review
‡9
1
|
|
919
|
|
|
‡a
1lineceritinibversusplatinumbasedchemotherapyinadvancedalkrearrangednonsmallcelllungcancerascend4arandomisedopenlabelphase3study
‡A
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
‡9
1
|
|
919
|
|
|
‡a
headandneckcanceremergingstrategiesadvancesandnewchallenges
‡A
Head and neck cancer emerging strategies: advances and new challenges
‡9
1
|
|
919
|
|
|
‡a
inductionchemotherapypriortosurgerywithorwithoutpostoperativeradiotherapyfororalcavitycancerpatientssystematicreviewandmetaanalysis
‡A
Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis.
‡9
1
|
|
919
|
|
|
‡a
influenceoftimebetweensurgeryandpostoperativeradiationtherapyandtotaltreatmenttimeinlocoregionalcontrolofpatientswithheadandneckcancerasinglecenterexperience
‡A
Influence of time between surgery and postoperative radiation therapy and total treatment time in locoregional control of patients with head and neck cancer: a single center experience
‡9
1
|
|
919
|
|
|
‡a
keynotecommentreimbursementformolecularlytargetedanticanceragents
‡A
Keynote comment: reimbursement for molecularly targeted anticancer agents
‡9
1
|
|
919
|
|
|
‡a
lungcancerandthecovid19pandemicrecommendationsfromthebrazilianthoraciconcologygroup
‡A
Lung Cancer and the COVID-19 pandemic: Recommendations from the Brazilian Thoracic Oncology Group
‡9
1
|
|
919
|
|
|
‡a
lungcancerinbrazil
‡A
Lung cancer in Brazil
‡9
1
|
|
919
|
|
|
‡a
managementofadvancedheadandnecksquamouscellcarcinomainelderlypatients
‡A
Management of advanced head and neck squamous cell carcinoma in elderly patients
‡9
1
|
|
919
|
|
|
‡a
metronomicoralcyclophosphamideplusprednisoneindocetaxelpretreatedpatientswithmetastaticcastrationresistantprostatecancer
‡A
Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer
‡9
1
|
|
919
|
|
|
‡a
nextgenerationsequencingofcirculatingtumordnaformetastaticnonsmallcelllungcanceradiscussiononitsimplementationinthebrazilianclinicalpractice
‡A
Next-generation sequencing of circulating tumor DNA for metastatic non-small cell lung cancer: a discussion on its implementation in the Brazilian clinical practice
‡9
1
|
|
919
|
|
|
‡a
oralmucositispreventionbylowlevellasertherapyinheadandneckcancerpatientsundergoingconcurrentchemoradiotherapyaphase3randomizedstudy
‡A
Oral Mucositis Prevention By Low-Level Laser Therapy in Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy: A Phase III Randomized Study
‡9
1
|
|
919
|
|
|
‡a
plasmaosteopontinlevelsinpatientswithheadandneckcancerundergoingchemoradiotherapy
‡A
Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy
‡9
1
|
|
919
|
|
|
‡a
realworldmoleculartestingandtreatmentpatternsinbrazilianpatientswithnewlydiagnosedlocallyadvancedormetastaticnsclc
‡A
Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC
‡9
1
|
|
919
|
|
|
‡a
renaleffectsofmoleculartargetedtherapiesinoncologyareviewbythecancerandthekidneyinternationalnetwork100kin
‡A
Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN).
‡9
1
|
|
919
|
|
|
‡a
responsestocrizotinibcanoccurinhighlevelmetamplifiednonsmallcelllungcancerindependentofmetexon14alterations
‡A
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations
‡9
1
|
|
919
|
|
|
‡a
reviewsideeffectsofapprovedmoleculartargetedtherapiesinsolidcancers
‡A
Review: side effects of approved molecular targeted therapies in solid cancers.
‡9
1
|
|
919
|
|
|
‡a
2primarycancersinheadandneckcancerpatientsachallengingentity
‡A
Second primary cancers in head and neck cancer patients: a challenging entity
‡9
1
|
|
919
|
|
|
‡a
sideeffectsofanticancermoleculartargetedtherapiesnotmonoclonalantibodies
‡A
Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
‡9
1
|
|
919
|
|
|
‡a
targetingtheimmunesysteminheadandneckcancer
‡A
Targeting the immune system in head and neck cancer
‡9
1
|
|
919
|
|
|
‡a
importanceofmolecularcharacterizationinlungcancer
‡A
The importance of molecular characterization in lung cancer
‡9
1
|
|
919
|
|
|
‡a
tonguecancerintheyoung
‡A
Tongue cancer in the young
‡9
1
|
|
919
|
|
|
‡a
advancedprostatecancerasacauseofoncogenicosteomalaciaanunderdiagnosedcondition
‡A
Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition
‡9
1
|
|
996
|
|
|
‡2
NKC|hka20181006109
|
|
996
|
|
|
‡2
LC|no2009090589
|
|
996
|
|
|
‡2
BLBNB|000384095
|
|
996
|
|
|
‡2
LC|n 50058834
|
|
996
|
|
|
‡2
DNB|1057707015
|
|
996
|
|
|
‡2
LC|n 81140399
|
|
996
|
|
|
‡2
DNB|137509316
|
|
996
|
|
|
‡2
ISNI|0000000026588595
|
|
996
|
|
|
‡2
ISNI|0000000040181441
|
|
996
|
|
|
‡2
NTA|323262856
|
|
996
|
|
|
‡2
BNF|16777179
|
|
996
|
|
|
‡2
ICCU|CUBV037173
|
|
996
|
|
|
‡2
LC|no2004082697
|
|
996
|
|
|
‡2
ISNI|0000000068413734
|
|
996
|
|
|
‡2
ISNI|0000000047354480
|
|
996
|
|
|
‡2
ISNI|0000000387971979
|
|
996
|
|
|
‡2
LC|no2008027452
|
|
996
|
|
|
‡2
LC|n 2006210812
|
|
996
|
|
|
‡2
PTBNP|201925
|
|
996
|
|
|
‡2
SUDOC|131132849
|
|
996
|
|
|
‡2
PTBNP|144252
|
|
996
|
|
|
‡2
LC|no2013071070
|
|
996
|
|
|
‡2
BLBNB|000153523
|
|
996
|
|
|
‡2
LC|n 84054263
|
|
996
|
|
|
‡2
PTBNP|1496945
|
|
996
|
|
|
‡2
PTBNP|536719
|
|
996
|
|
|
‡2
DNB|138404933
|
|
996
|
|
|
‡2
PTBNP|247950
|
|
996
|
|
|
‡2
ISNI|0000000067346058
|
|
996
|
|
|
‡2
ISNI|0000000060471171
|
|
996
|
|
|
‡2
BLBNB|000466178
|
|
996
|
|
|
‡2
ISNI|0000000109071305
|
|
996
|
|
|
‡2
BLBNB|000499955
|
|
996
|
|
|
‡2
LC|n 79125491
|
|
996
|
|
|
‡2
LC|n 84031686
|
|
996
|
|
|
‡2
NLA|000061541347
|
|
996
|
|
|
‡2
ISNI|0000000072453202
|
|
996
|
|
|
‡2
LC|n 2009033004
|
|
996
|
|
|
‡2
ISNI|000000002460650X
|
|
996
|
|
|
‡2
DNB|1159091862
|
|
996
|
|
|
‡2
DNB|1057184098
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
